MA44733A - Procédé de traitement du cancer du sein négatif triple - Google Patents
Procédé de traitement du cancer du sein négatif tripleInfo
- Publication number
- MA44733A MA44733A MA044733A MA44733A MA44733A MA 44733 A MA44733 A MA 44733A MA 044733 A MA044733 A MA 044733A MA 44733 A MA44733 A MA 44733A MA 44733 A MA44733 A MA 44733A
- Authority
- MA
- Morocco
- Prior art keywords
- breast cancer
- treatment method
- cancer treatment
- negative breast
- triple negative
- Prior art date
Links
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 title 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324711P | 2016-04-19 | 2016-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44733A true MA44733A (fr) | 2019-02-27 |
Family
ID=58699250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044733A MA44733A (fr) | 2016-04-19 | 2017-04-18 | Procédé de traitement du cancer du sein négatif triple |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20210030737A1 (fr) |
| EP (1) | EP3445361A1 (fr) |
| CN (1) | CN109475545A (fr) |
| CA (1) | CA3021445A1 (fr) |
| MA (1) | MA44733A (fr) |
| RU (1) | RU2757905C2 (fr) |
| WO (1) | WO2017184597A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2350075T3 (da) | 2008-09-22 | 2014-05-26 | Array Biopharma Inc | Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer |
| PT3106463T (pt) | 2008-10-22 | 2018-05-18 | Array Biopharma Inc | Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| RU2735545C2 (ru) | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
| EP3218380B1 (fr) | 2014-11-16 | 2021-03-17 | Array Biopharma, Inc. | Préparation d'une forme cristalline d'hydrogénosulfate de (s)-n-(5-((r)-2-(2,5-difluorophényl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| TN2019000271A1 (en) | 2015-10-26 | 2021-01-07 | Univ Colorado Regents | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| IL304018A (en) | 2016-04-04 | 2023-08-01 | Loxo Oncology Inc | Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| ES2952056T3 (es) | 2016-05-18 | 2023-10-26 | Loxo Oncology Inc | Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| MX389966B (es) * | 2017-01-20 | 2025-03-20 | Exelixis Inc | Combinaciones de cabozantinib y atezolizumab para tratar cancer. |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| MY210421A (en) | 2018-01-26 | 2025-09-22 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| US20210023086A1 (en) * | 2018-03-29 | 2021-01-28 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
| US20190381043A1 (en) * | 2018-06-13 | 2019-12-19 | King Faisal Specialist Hospital & Research Centre | Method of Treatment of Cancer |
| AU2019285066B2 (en) | 2018-06-15 | 2024-06-13 | Handa Pharmaceuticals, Inc. | Kinase inhibitor salts and compositions thereof |
| AU2019364258A1 (en) * | 2018-10-21 | 2021-06-03 | Slsg Limited Llc | Combination immunotherapy for treatment of triple-negative breast cancer |
| US20230392196A1 (en) * | 2022-06-06 | 2023-12-07 | Applied Materials, Inc. | RNA retrieval process for preparing formalin-fixed, paraffin-embedded (FFPE) tissue samples for in situ hybridization |
| EP4658271A1 (fr) | 2023-01-31 | 2025-12-10 | Handa Oncology, LLC | Compositions de cabozantinib améliorées et procédés d'utilisation |
| KR20250156321A (ko) * | 2024-04-25 | 2025-11-03 | 한국 한의학 연구원 | 카보잔티닙을 유효성분으로 함유하는 항암제 내성암의 예방 또는 치료용 약학 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130012465A1 (en) * | 2009-12-07 | 2013-01-10 | Boehringer Ingelheim International Gmbh | Bibw 2992 for use in the treatment of triple negative breast cancer |
| KR20180056807A (ko) * | 2010-07-16 | 2018-05-29 | 엑셀리시스, 인코포레이티드 | C-met 조절제 약제학적 조성물 |
| CA2808236A1 (fr) * | 2010-08-31 | 2012-03-08 | Genentech, Inc. | Biomarqueurs et procedes de traitement |
| EP2650682A1 (fr) * | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Esters asymétriques d'acides gras utiles en tant que lubrifiants |
| CN106999734B (zh) * | 2014-09-29 | 2020-06-16 | 得克萨斯大学体系董事会 | 针对parp抑制剂的应答的预测和靶向c-met和parp1的组合疗法 |
-
2017
- 2017-04-18 EP EP17722917.6A patent/EP3445361A1/fr not_active Withdrawn
- 2017-04-18 RU RU2018136749A patent/RU2757905C2/ru active
- 2017-04-18 CN CN201780023462.7A patent/CN109475545A/zh active Pending
- 2017-04-18 CA CA3021445A patent/CA3021445A1/fr active Pending
- 2017-04-18 MA MA044733A patent/MA44733A/fr unknown
- 2017-04-18 US US16/095,221 patent/US20210030737A1/en not_active Abandoned
- 2017-04-18 WO PCT/US2017/028129 patent/WO2017184597A1/fr not_active Ceased
-
2023
- 2023-10-19 US US18/490,248 patent/US20240148714A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018136749A3 (fr) | 2020-08-20 |
| RU2018136749A (ru) | 2020-05-19 |
| CA3021445A1 (fr) | 2017-10-26 |
| WO2017184597A1 (fr) | 2017-10-26 |
| EP3445361A1 (fr) | 2019-02-27 |
| CN109475545A (zh) | 2019-03-15 |
| RU2757905C2 (ru) | 2021-10-22 |
| US20240148714A1 (en) | 2024-05-09 |
| US20210030737A1 (en) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44733A (fr) | Procédé de traitement du cancer du sein négatif triple | |
| EP3684420A4 (fr) | Méthodes de traitement du cancer du sein triple négatif | |
| EP3288382A4 (fr) | Procédés de traitement du cancer | |
| EP3488001A4 (fr) | Traitement du cancer | |
| MA50056A (fr) | Procédés de traitement de tumeur | |
| PL3288581T3 (pl) | Sposób leczenia nowotworu | |
| MA47501A (fr) | Dérivé de di-nucléotides cycliques pour le traitement du cancer | |
| EP3399861A4 (fr) | Procédés de traitement du cancer par interféron | |
| EP3341080A4 (fr) | Méthode de traitement du cancer | |
| MA41555A (fr) | Polythérapie pour le traitement du cancer | |
| IL284875A (en) | Lasofoxifene treatment of breast cancer | |
| EP3820461A4 (fr) | Méthode de traitement du cancer | |
| MA45429A (fr) | Polythérapie pour le traitement du cancer | |
| MA47408A (fr) | Traitement du cancer | |
| EP3389634A4 (fr) | Méthodes de traitement du cancer | |
| EP3389645A4 (fr) | Combinaisons pour le traitement du cancer | |
| MA46361A (fr) | Traitement du cancer de la prostate | |
| EP3442946A4 (fr) | Procédés de traitement du cancer | |
| EP3359255A4 (fr) | Polythérapies pour le traitement du cancer | |
| MA45780A (fr) | Méthodes de traitement du cancer de la prostate | |
| EP3606531A4 (fr) | Méthodes de traitement du cancer | |
| MA41123A (fr) | Polythérapie pour le traitement du cancer | |
| EP3684342A4 (fr) | Procédé de traitement | |
| EP3389652A4 (fr) | Méthodes de traitement du cancer | |
| FR3039368B1 (fr) | Procede de traitement cosmetique |